Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Riley

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Gastroenterology|August 15, 2022
Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective CohortsKeming Yang, Yin Cao, Carino Gurjao, et al.
Nature Genetics|December 11, 2012
Emergence and global spread of epidemic healthcare-associated Clostridium difficileMiao He, Fabio Miyajima, Paul Roberts, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Gastroenterology|August 15, 2022
Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective CohortsKeming Yang, Yin Cao, Carino Gurjao, et al.
Nature Genetics|December 11, 2012
Emergence and global spread of epidemic healthcare-associated Clostridium difficileMiao He, Fabio Miyajima, Paul Roberts, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 2